Activation of the HIF1α/TIMP1/MT6-MMP pathway is associated with invasion in pituitary null cell adenomas

in Endocrine-Related Cancer
Authors:
Shengyuan Yu Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China

Search for other papers by Shengyuan Yu in
Current site
Google Scholar
PubMed Close
,
Quanxi Duan Department of Neurosurgery, Juxian People’s Hospital, Rizhao, Shandong, China

Search for other papers by Quanxi Duan in
Current site
Google Scholar
PubMed Close
,
Changcun Niu Department of Neurosurgery, Traditional Chinese Medical Hospital of Taian, Taian, Shandong, China

Search for other papers by Changcun Niu in
Current site
Google Scholar
PubMed Close
, and
Chengzhi Mu Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China

Search for other papers by Chengzhi Mu in
Current site
Google Scholar
PubMed Close
https://orcid.org/0009-0005-9231-8677

Correspondence should be addressed to C Mu: yushengyuan@sdslyy.wecom.work
DOI:
https://doi.org/10.1530/ERC-24-0146
Volume/Issue:
Volume 32: Issue 2
Article Type:
Research Article
Article ID:
e240146
Online Publication Date:
10 Jan 2025
Copyright:
© the author(s) 2025
Restricted access
Rent on DeepDyve

Sign up for journal news

Non-functioning pituitary adenomas (NFPAs) are a highly heterogeneous group and often show invasion, but few studies have explored the invasion mechanism and biomarkers for specific subtypes. This study was designed to describe the role of HIF1α and its downstream genes in specific subtypes of NFPAs. Specimens were classified into two subtypes of NFPAs: 46 null cell adenomas (28 invasive and 18 noninvasive) and 46 oncocytomas (11 invasive and 35 noninvasive). HIF1α, TIMP1, MT6-MMP, ECAD and NCAD were detected by qRT-PCR, western blot or immunohistochemistry in tumor tissue. The transwell assay was performed to measure the effects of HIF1α on tumor cell invasion in GH3 and GT1-1 cells. TIMP1, MT6-MMP, ECAD and NCAD were detected by western blot in HIF1α overexpressed GT1-1 cells. HIF1α mRNA and protein level was significantly upregulated in invasive pituitary null cell adenomas but not in invasive pituitary oncocytoma. The TIMP1 mRNA and protein level was significantly downregulated and MT6-MMP mRNA and protein level was significantly upregulated in invasive pituitary null cell adenomas. Meanwhile, there were no significant differences in epithelial–mesenchymal transition (EMT) markers, ECAD and NCAD, between invasive and noninvasive pituitary null cell adenomas. The overexpression of HIF1α promoted the invasive capability of pituitary adenoma cells in vitro. Regarding the molecular mechanism, HIF1α overexpression could downregulate TIMP1 and upregulate MT6-MMP expression levels but did not affect EMT markers’ expression. Our results suggested that HIF1α might contribute to the invasion of pituitary null cell adenomas through activating HIF1α/TIMP1/MT6-MMP pathway but not EMT.

Endocrine-Related Cancer is committed to supporting researchers in demonstrating the impact of their articles published in the journal.

The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.

More information is on the Reasons to publish page.

Sept 2018 onwards Past Year Past 30 Days
Full Text Views 13 13 12
PDF Downloads 21 21 18

 

  • Collapse
  • Expand
Print ISSN:
1351-0088
Online ISSN:
1479-6821
Copyright:
© the author(s) 2025
Article ID:
e240146
Received Date:
27 Jun 2024
Rev-recd:
13 Nov 2024
Accepted Date:
13 Dec 2024
Print Publication Date:
01 Feb 2025
Online Publication Date:
10 Jan 2025
Keywords:
non-functioning pituitary adenomas; null cell adenoma; invasion; HIF1α; MT6-MMP

  • Ekwall AK, Eisler T, Anderberg C, et al. 2011 The tumour-associated glycoprotein podoplanin is expressed in fibroblast-like synoviocytes of the hyperplastic synovial lining layer in rheumatoid arthritis. Arthritis Res Ther 13 R40. (https://doi.org/10.1186/ar3274)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • English WR, Velasco G, Stracke JO, et al. 2001 Catalytic activities of membrane-type 6 matrix metalloproteinase (MMP25). FEBS Lett 491 137–142. (https://doi.org/10.1016/s0014-5793(01)02150-0)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Enns L & Ladiges W 2012 Mitochondrial redox signaling and cancer invasiveness. J Bioenerg Biomembr 44 635–638. (https://doi.org/10.1007/s10863-012-9467-7)

  • Fougner SL, Lekva T, Borota OC, et al. 2010 The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J Clin Endocrinol Metab 95 2334–2342. (https://doi.org/10.1210/jc.2009-2197)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Fujiwara S, Nakagawa K, Harada H, et al. 2007 Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int J Oncol 30 793–802. (https://doi.org/10.3892/ijo.30.4.793)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Gasparre G, Romeo G, Rugolo M, et al. 2011 Learning from oncocytic tumors: why choose inefficient mitochondria? Biochim Biophys Acta 1807 633–642. (https://doi.org/10.1016/j.bbabio.2010.08.006)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Greenman Y & Melmed S 1996 Diagnosis and management of nonfunctioning pituitary tumors. Annu Rev Med 47 95–106. (https://doi.org/10.1146/annurev.med.47.1.95)

  • Holm R 1995 Null cell adenomas and oncocytomas of the pituitary gland. Pathol Res Pract 191 348–352. (https://doi.org/10.1016/s0344-0338(11)80888-5)

  • Hussaini IM, Trotter C, Zhao Y, et al. 2007 Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. Am J Pathol 170 356–365. (https://doi.org/10.2353/ajpath.2007.060736)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Kalluri R & Weinberg RA 2009 The basics of epithelial-mesenchymal transition. J Clin Invest 119 1420–1428. (https://doi.org/10.1172/jci39104)

  • Knosp E, Steiner E, Kitz K, et al. 1993 Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33 610–617. (https://doi.org/10.1227/00006123-199310000-00008)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Kolitz T & Greenman Y 2023 Refractory nonfunctioning pituitary adenomas. Pituitary 26 278–280. (https://doi.org/10.1007/s11102-023-01298-4)

  • Liang Y, Guan C, Li K, et al. 2020 MMP25 regulates immune infiltration level and survival outcome in head and neck cancer patients. Front Oncol 10 1088. (https://doi.org/10.3389/fonc.2020.01088)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Liu W, Kunishio K, Matsumoto Y, et al. 2005 Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas. J Clin Neurosci 12 791–794. (https://doi.org/10.1016/j.jocn.2005.03.010)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Mayson SE & Snyder PJ 2014 Silent (clinically nonfunctioning) pituitary adenomas. J Neurooncol 117 429–436. (https://doi.org/10.1007/s11060-014-1425-2)

  • Porcelli AM, Ghelli A, Ceccarelli C, et al. 2010 The genetic and metabolic signature of oncocytic transformation implicates HIF1α destabilization. Hum Mol Genet 19 1019–1032. (https://doi.org/10.1093/hmg/ddp566)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Qannita RA, Alalami AI, Harb AA, et al. 2024 Targeting hypoxia-inducible factor-1 (HIF-1) in cancer: emerging therapeutic strategies and pathway regulation. Pharmaceuticals 17 195. (https://doi.org/10.3390/ph17020195)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Semenza GL 2010 Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29 625–634. (https://doi.org/10.1038/onc.2009.441)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Taguchi A, Kinoshita Y, Amatya VJ, et al. 2023 Differences in invasiveness and recurrence rate among nonfunctioning pituitary neuroendocrine tumors depending on tumor subtype. Neurosurg Rev 46 317. (https://doi.org/10.1007/s10143-023-02234-7)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Tanaka N & Sakamoto T 2023 MT1-MMP as a key regulator of metastasis. Cells 12 2187. (https://doi.org/10.3390/cells12172187)

  • Tritos NA & Miller KK 2023 Diagnosis and management of pituitary adenomas: a review. JAMA 329 1386–1398. (https://doi.org/10.1001/jama.2023.5444)

  • Velasco G, Cal S, Merlos-Suarez A, et al. 2000 Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors. Cancer Res 60 877–882.

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Vidal S, Horvath E, Kovacs K, et al. 2003 Expression of hypoxia-inducible factor-1alpha (HIF-1alpha) in pituitary tumours. Histol Histopathol 18 679–686. (https://doi.org/10.14670/HH-18.679)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Wilson CB 1984 A decade of pituitary microsurgery. The Herbert Olivecrona lecture. J Neurosurg 61 814–833. (https://doi.org/10.3171/jns.1984.61.5.0814)

  • Yamada S, Ohyama K, Taguchi M, et al. 2007 A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 61 580–585. (https://doi.org/10.1227/01.neu.0000290906.53685.79)

    • PubMed
    • Search Google Scholar
    • Export Citation